In the new study, published online Oct. 4 in The New England Journal of Medicine, Eichler and his team treated 17 boys ages 17 or younger with a single dose of the experimental gene therapy. When the researchers followed up on the boys two years later, 15 were functioning without any major disability or progression of their disease. The other two had died, one from a worsening of the disease and the other from complications of a donor transplant he got after he withdrew from the study.
For the gene therapy, the children had their own stem cells harvested from their blood rather than bone marrow. Then, scientists used a unique tool to infuse the cells in a lab with the healthy ABCD1 gene: a lentivirus made from a disabled form of HIV. The lentivirus acts as a “vector,” carrying and inserting the healthy gene into the stem cell DNA.
“These vectors are kind of like living medicines,” said Dr. David Williams, the chief scientific officer at Boston Children’s Hospital and the senior author of the study. Once in the body, these altered blood stem cells constantly regenerate to keep treating the patient’s disease. The advantage of using disabled HIV over other viral carriers is that HIV actually delivers the healthy gene more safely, without apparently altering any neighboring DNA, Williams told Live Science.
When the modified stem cells are transplanted back into the patient two months later, the cells multiply in the bone marrow and eventually find their way into the brain through the bloodstream. There, they replace microglial cells, breaking down fatty acids and supporting neurons to prevent any further brain damage from occurring.
“This is very exciting, not just for kids and families with adrenoleukodystrophy, but also as a breakthrough for other disorders that [affect] the brain,” said Amanda Bergner, a genetic counselor at Columbia University who was not involved in the study. Neurological disorders have traditionally been hard to target and treat because of how the brain is sealed off from the rest of the body, she said.
But the study’s success has prompted the therapy maker and study sponsor — biotech company Bluebird Bio — to include an additional eight boys in the trial. Separate research is also focused on how boys receiving gene therapy fare compared to those who had bone-marrow transplants. And Bluebird Bio scientists, some of whom were also involved in the study, have indicated that they plan to pursue FDA approval for the therapy.
H/t reader kevin a.
* * *